Literature DB >> 22646078

Approaches to the rational design of selective melanocortin receptor antagonists.

Victor J Hruby1, Minying Cai, Joel Nyberg, Dhanasekaran Muthu.   

Abstract

INTRODUCTION: When establishing the physiological roles of specific receptors in normal and disease states, it is critical to have selective antagonist ligands for each receptor in a receptor system with several subtypes. The melanocortin receptors have five subtypes referred to as the melanocortin 1 receptor, melanocortin 2 receptor, melanocortin 3 receptor, melanocortin 4 receptor and melanocortin 5 receptor, and they are of critical importance for many aspects of human health and disease. AREAS COVERED: This article reviews the current efforts to design selective antagonistic ligands for the five human melanocortin receptors summarizing the currently published orthosteric and allosteric antagonists for each of these receptors. EXPERT OPINION: Though there has been progress, there are still few drugs available that address the many significant biological activities and diseases that are associated with these receptors, which is possibly due to the lack of receptor selectivity that these designed ligands are currently showing. The authors believe that further studies into the antagonists' 3D conformational and topographical properties in addition to future mutagenesis studies will provide greater insight into these ligands which could play a role in the treatment of various diseases in the future.

Entities:  

Year:  2011        PMID: 22646078      PMCID: PMC4608743          DOI: 10.1517/17460441.2011.565743

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  66 in total

1.  Alpha-melanocyte-stimulating hormone plays an important role in the onset of pollinosis in a pollen allergy mouse model.

Authors:  Keiichi Hiramoto; Maki Hashimoto; Kumi Orita; Mika Jikumaru; Eisuke F Sato; Masayasu Inoue
Journal:  Int Arch Allergy Immunol       Date:  2010-03-30       Impact factor: 2.749

2.  Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors.

Authors:  Malcolm J Kavarana; Dev Trivedi; Minying Cai; Jinfa Ying; Matthew Hammer; Christopher Cabello; Paolo Grieco; Guoxia Han; Victor J Hruby
Journal:  J Med Chem       Date:  2002-06-06       Impact factor: 7.446

3.  Novel 3D pharmacophore of alpha-MSH/gamma-MSH hybrids leads to selective human MC1R and MC3R analogues.

Authors:  Minying Cai; Alexander V Mayorov; Christopher Cabello; Magda Stankova; Dev Trivedi; Victor J Hruby
Journal:  J Med Chem       Date:  2005-03-24       Impact factor: 7.446

4.  Sex-specific mediation of opioid-induced hyperalgesia by the melanocortin-1 receptor.

Authors:  Aaron Juni; Minying Cai; Magda Stankova; Amanda R Waxman; Caroline Arout; Gad Klein; Albert Dahan; Victor J Hruby; Jeffrey S Mogil; Benjamin Kest
Journal:  Anesthesiology       Date:  2010-01       Impact factor: 7.892

5.  Long term orexigenic effect of a novel melanocortin 4 receptor selective antagonist.

Authors:  G V Skuladottir; L Jonsson; J O Skarphedinsson; F Mutulis; R Muceniece; A Raine; I Mutule; J Helgason; P Prusis; J E Wikberg; H B Schiöth
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

6.  Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction.

Authors:  H Wessells; D Gralnek; R Dorr; V J Hruby; M E Hadley; N Levine
Journal:  Urology       Date:  2000-10-01       Impact factor: 2.649

7.  Design of novel chimeric melanotropin-deltorphin analogues. Discovery of the first potent human melanocortin 1 receptor antagonist.

Authors:  G Han; J M Quillan; K Carlson; W Sadée; V J Hruby
Journal:  J Med Chem       Date:  2003-02-27       Impact factor: 7.446

8.  Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor.

Authors:  Shigeyuki Chaki; Shiho Hirota; Takeo Funakoshi; Yoshiko Suzuki; Sayoko Suetake; Taketoshi Okubo; Takaaki Ishii; Atsuro Nakazato; Shigeru Okuyama
Journal:  J Pharmacol Exp Ther       Date:  2003-02       Impact factor: 4.030

9.  [Synthetic peptide KKRR corresponding to the human ACTH fragment 15-18 is an antagonist of the ACTH receptor].

Authors:  Iu A Kovalitskaia; A A Kolobov; E A Kampe-Nemm; V V Iurovskií; V B Sadovnikov; V M Lipkin; E V Navolotskaia
Journal:  Bioorg Khim       Date:  2008 Jan-Feb

10.  4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity.

Authors:  T K Sawyer; P J Sanfilippo; V J Hruby; M H Engel; C B Heward; J B Burnett; M E Hadley
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

View more
  6 in total

1.  An unusual conformation of γ-melanocyte-stimulating hormone analogues leads to a selective human melanocortin 1 receptor antagonist for targeting melanoma cells.

Authors:  Minying Cai; Magda Stankova; Dhanasekaran Muthu; Alexander Mayorov; Zhehui Yang; Devendra Trivedi; Christopher Cabello; Victor J Hruby
Journal:  Biochemistry       Date:  2013-01-15       Impact factor: 3.162

2.  Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer.

Authors:  Shanthi Kanthala; Sashikanth Banappagari; Ameya Gokhale; Yong-Yu Liu; Gu Xin; Yunfeng Zhao; Seetharama Jois
Journal:  Chem Biol Drug Des       Date:  2014-11-06       Impact factor: 2.817

Review 3.  Novel approaches to the design of bioavailable melanotropins.

Authors:  Yang Zhou; Minying Cai
Journal:  Expert Opin Drug Discov       Date:  2017-07-12       Impact factor: 6.098

4.  Development of Macrocyclic Peptidomimetics Containing Constrained α,α-Dialkylated Amino Acids with Potent and Selective Activity at Human Melanocortin Receptors.

Authors:  Francesco Merlino; Yang Zhou; Minying Cai; Alfonso Carotenuto; Ali M Yousif; Diego Brancaccio; Salvatore Di Maro; Silvia Zappavigna; Antonio Limatola; Ettore Novellino; Paolo Grieco; Victor J Hruby
Journal:  J Med Chem       Date:  2018-04-25       Impact factor: 7.446

5.  Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3.

Authors:  Shanthi Kanthala; Ted Gauthier; Seetharama Satyanarayanajois
Journal:  Biopolymers       Date:  2014-06       Impact factor: 2.505

Review 6.  The Opioid System and Food Intake: Use of Opiate Antagonists in Treatment of Binge Eating Disorder and Abnormal Eating Behavior.

Authors:  Leon P Valbrun; Valeriy Zvonarev
Journal:  J Clin Med Res       Date:  2020-02-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.